Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | CheckMate-743 study in mesothelioma

Dean Fennell • 26 May 2020
ASCO 2020
Lung Cancer Mesothelioma Antibodies Carboplatin Cisplatin Ipilimumab Nivolumab Pemetrexed

Dean Fennell, PhD, FRCP, of the University Hospitals Of Leicester NHS Trust, Leicester, UK discusses the result of the CheckMate-743 study (NCT02899299) which evaluated the efficacy of nivolumab combined with ipilimumab versus pemetrexed and cisplatin or carboplatin as first line therapy in unresectable pleural mesothelioma patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Dean Fennell

1:14
ATOMIC: treating mesothelioma with an arginine-degrading enzyme and combination chemotherapy
Dean Fennell • 27 Apr 2023
3:34
Role of immunotherapy in the management of mesothelioma
Dean Fennell • 31 Mar 2023
6:43
Personalized medicine in mesothelioma
Dean Fennell • 31 Mar 2023
1:54
Abemaciclib in patients with p16ink4a negative, relapsed mesothelioma
Dean Fennell • 21 May 2021

Related Videos

3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals